Browse by ▼

Dendreon Corp

  • Why Questcor Is Undervalued

    By Ishtiaq Ahmed - May 8, 2013 | Tickers: DNDN, QCOR, SRPT

    Questcor Pharmaceuticals (NASDAQ: QCOR) has faced the affects of bad press more than once in the past. The stock lost more than half of its value last year, after reports about its questionable marketing practices spurred a federal investigation. While that drop was extremely painful for long-term investors, it gave speculators and short-term traders an opportunity to make substantial profits, and let long-term investors add to their positions. The stock more »

  • Galena: Improving Cancer Vaccines for the Future

    By Terry Chrisomalis - May 7, 2013 | Tickers: DNDN, GALE, VICL

    There are some vaccine companies that have game changing technologies to target different types of cancer. One such company looking to improve upon cancer vaccines, is a small cap biotech company known as Galena Biopharma (NASDAQ: GALE). The company has many types of vaccine candidates in its pipeline, and is currently in one phase 3 study for breast cancer. The vaccine candidate to treat breast cancer is called NeuVax. 

    The more »

  • Galena Improving Cancer Vaccines For The Future

    By Terry Chrisomalis - May 1, 2013 | Tickers: DNDN, GALE, VICL

    There are some vaccine companies that have game changing technologies to target different types of cancer. One such company looking to improve upon cancer vaccines, is a small cap biotech company known as Galena Biopharma (NASDAQ: GALE). The company has many types of vaccine candidates in its pipeline, and is currently in one phase 3 study for Breast Cancer. The vaccine candidate to treat breast cancer is called NeuVax. 

    The more »

  • Is Medivation Still A Buy?

    By Terry Chrisomalis - April 18, 2013 | Tickers: DNDN, JNJ, MDVN

    It seems that Medivation (NASDAQ: MDVN) had a great year in 2012, and so far the momentum seems it will keep going through all of 2013 as well. Medivation is a biotechnology stock that targets diseases with limited treatment options. The company had a rough past when it had partnered with Pfizer, with a drug known as Dimebon. 

    Dimebon had made it up to Phase III, where it had failed more »

  • Should You Sell These Biotechnology Stocks

    By Mohsin Saeed - April 14, 2013 | Tickers: CBM, DNDN, IDIX

    Bio-pharmaceutical companies usually make for some very high risk investments. This is because there are a number of factors that cannot be predicted accurately.The valuations skyrocket on drug approvals, but the actual performance in the market is an entirely different story. The following three stock have seen heavy institutional selling in the last few months, and I believe investors should stay away from them for the time. 

    Cambrex Corporation more »

  • Adage Capital Management Owns 5.4% of This Biotech Stock

    By Meena Krishnamsetty - April 10, 2013 | Tickers: ABT, AMRN, BIIB, DNDN, MDVN

    According to a 13G filed with the SEC, Adage Capital Management, a large hedge fund managed by Phil Gross and Robert Atchinson, owns just over 4 million shares of Medivation (NASDAQ: MDVN), a $3.6 billion market cap biotechnology company. Our database of 13F filings shows Adage with a position of 2.1 million shares as of the beginning of January, so in the last three months the fund has more »

  • Is Medivation Still A Buy?

    By Terry Chrisomalis - April 9, 2013 | Tickers: DNDN, JNJ, MDVN

    It seems that Medivation (NASDAQ: MDVN) had a great year in 2012, and so far the momentum seems it will keep going through all of 2013 as well. Medivation is a biotechnology stock that targets diseases with limited treatment options. The company had a rough past though, when it had partnered with Pfizer with a drug known as Dimebon. 

    Dimebon had made it up to phase three, where it had more »

  • Adage Capital Management Owns 5.4% of This Biotech Stock

    By Meena Krishnamsetty - April 8, 2013 | Tickers: ABT, AMRN, BIIB, DNDN, MDVN

    According to a 13G filed with the SEC, Adage Capital Management, a large hedge fund managed by Phil Gross and Robert Atchinson, owns just over 4 million shares of Medivation (NASDAQ: MDVN), a $3.6 billion market cap biotechnology company. Our database of 13F filings shows Adage with a position of 2.1 million shares as of the beginning of January, so in the last three months the fund has more »

  • A Magical Drug that Could Change Lives

    By Piyush Arora - March 25, 2013 | Tickers: DNDN, JNJ, MDVN

    The biotech sector is perhaps the most volatile and risk-prone sector in the market, but investors still love it. Medical science is leaping forward and new drugs keep hitting the Street, but the hunt for the “safer and more effective drug” is always on. It’s for this reason that we often see contrarians being rewarded massively for their daring positions. The company in focus is Dendreon Corporation (NASDAQ: DNDNmore »)

  • Revitalize Your Portfolio With This Drugmaker

    By Rahul Giria - March 11, 2013 | Tickers: DNDN, MDVN, NVS

    Dendreon (NASDAQ: DNDN) has been struggling since summer 2011, when the company decreased its sales estimates for its flagship cancer drug Provenge. As a result, shares have taken a huge hit since then. Provenge faces stiff competition from Medivation’s (NASDAQ: MDVN) Xtandi and Johnson & Johnson’s (NYSE: JNJ) Zytiga. Yet I believe now's the right time to invest in Dendreon's stock. Let assess why.

    Financials

    Dendreon surprised more »

  • Should you Buy this Company on Earnings?

    By Mohsin Saeed - March 5, 2013 | Tickers: ALPMY.PK, DNDN, JNJ

    Dendreon Corp. (NASDAQ: DNDN) investors have been on a perpetual roller coaster ride due to shifting expectations from Provenge. The company reported its quarterly results the other day and beat Street estimates. However, Provenge faces severe competition from Astellas’ (NASDAQOTH: ALPMY) Xtandi and Johnson & Johnson’s (NYSE: JNJ) Zytinga. I believe that despite the recent positives it’s still too soon to be bullish on Dendreon, and I advise investors more »

  • Are Any of these Stocks Worth Buying After Earnings?

    By Brian Nichols - February 28, 2013 | Tickers: DDD, DNDN, LOW

    Earnings and earning-related news is the number one catalyst for stock movement. A strong quarter can dictate the direction of a stock for the following three months as can a bad quarter; in the past I have written in detail about such subjects, a domino effect following a strong or bad quarter. In this piece I am looking at three stocks with high profile earning releases. Then, I am determining more »

  • Can this Bio-Pharmaceutical Rise Again?

    By Waqar Saif - February 14, 2013 | Tickers: ALPMY.PK, DNDN, JNJ

    Shares of Dendreon (NASDAQ: DNDN) have seen an epic decline due to weak sales numbers for its star drug Provenge. The drug has missed analyst expectations and has failed to justify high valuations for its creator. I believe the company is correctly priced at these levels and there is little room for an upside. In order to warrant better valuations in the future, company management should be focusing on strengthening more »

  • Will Cost Cutting Offset Competitive Pressures For This Biotech In 2013?

    By Jordo Bivona - February 6, 2013 | Tickers: ABBV, DNDN, JNJ, MDVN

    Dendreon (NASDAQ: DNDN) is recovering from lackluster sales of its sole drug on the market, Provenge. The prostate cancer treatment has been hit hard by reimbursement concerns that have led the company to make some big cuts, including the closing of a production plant and layoffs, to make up for lost sales. Have these changes been enough? With a number of other prostate cancer drugs on the market, it is more »

  • JNJ Looks Good, But Is There Enough Momentum?

    By Richard Saintvilus - January 20, 2013 | Tickers: ARNA, DNDN, JNJ

    Regardless of what you’ve heard, size always matters – even in business. Otherwise, the now infamous “Too big to fail” expression would never be used to reference every perceived villainous operation on Wall Street. Conversely, there are also those that are “Too big to succeed.”

    Healthcare giant Johnson & Johnson (NYSE: JNJ) is the perfect example. Although the company has been rejuvenated following its merger with Synthes, I worry that JNJ more »

  • 3 Top Bullish Stocks On The Run

    By Nick Chiu - January 17, 2013 | Tickers: DNDN, GNW, GOOG, IACI, MSFT, YHOO

    On January 16, 2013, the market sentiment is driven by extreme greed now with Fear & Greed Index at 85, which had decreased from the previous closing of 89. As reported by CBOE, the total put/call ratio for today was 0.87, and the index put/call ratio was 0.87. The equity put/call ratio was 0.75, and the CBOE volatility index (VIX) put/call ratio was 0 more »

  • Five High-Profile Stocks Moving Higher

    By Brian Nichols - January 14, 2013 | Tickers: ALU, BBRY, DNDN, HPQ

    A common theme of 2013 has been for previous years’ laggards to rally higher, showing a new-found level of interest. I suppose this makes sense as super-stock Apple falls into uncharted territory. Investors are now looking for value in unfamiliar places, and these stocks continued to rally on Monday.

    Company

    Ticker

    2013 Performance

    5-Year Performance

    Research in Motion

    (NASDAQ: BBRY)

    25%

    (87%)

    Dendreon

    (NASDAQ: DNDN)

    22%

    (54%)*

    Alcatel-Lucent

    (NYSE: ALUmore »)

  • What’s Moving These Biotechs?

    By Brian Nichols - January 14, 2013 | Tickers: FOLD, DNDN, PRGO, TSPT

    A number of biotechs of all sizes saw significant price action last week, specifically on Friday. It wasn’t just gainers that made the headlines, but also stocks seeing a significant decline. Therefore, I am looking at the best and worst, performing biotechs to determine what moved them and how to play the movement.

    Dendreon (NASDAQ: DNDN)

    Dendreon is probably the most controversial biotech stock in the market, due to more »

  • Is the Optimism Surrounding Provenge Reason to Buy?

    By Jordo Bivona - January 14, 2013 | Tickers: DNDN, JNJ, MDVN, NVS, TEVA

    Dendreon (NASDAQ: DNDN) recently sold its immunotherapy manufacturing facility based in Morris Plains, New Jersey to Novartis (NYSE: NVS) for $43 million in cash.

    The manufacturing facility has the capability to manufacture Provenge, the first cellular immunotherapy approved in the U.S. for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. The sale is part of a 12 month restructuring plan in which the company decided more »

  • Small Cap Movers with Strong Analyst Outlooks

    By Brian Nichols - January 12, 2013 | Tickers: CATM, DNDN, SODA

    We saw a number of strong performers from the small-cap space on Friday. These are stocks that had key developments that could very well lead to multi-day or multi-month rallies. However, these gains were also pushed higher by a number of analyst calls. Therefore, I am looking at three stocks that moved higher with a market cap under $1.5 billion that were also upgraded by analysts.

    Company

    Ticker

    Firm more »

  • Page 1 of 3